Related Experiment Videos
Flow cytometric DNA measurement in benign and malignant human thyroid tissues
Y Mizukami1, A Nonomura, T Michigishi
1Pathology Section, Kanazawa University Hospital, Japan.
Anticancer Research
|November 1, 1992
Summary
Aneuploidy, an abnormal number of chromosomes, was evaluated in thyroid tissues. DNA flow cytometry found aneuploidy in various thyroid tumors, but not in non-neoplastic lesions, suggesting its utility in distinguishing benign from malignant thyroid conditions.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Aneuploidy is a hallmark of cancer.
- Understanding aneuploidy in thyroid lesions can aid in diagnosis and prognosis.
Purpose of the Study:
- To evaluate the occurrence of aneuploidy in various thyroid tissues using DNA flow cytometry.
- To determine the potential of DNA content analysis in differentiating neoplastic from non-neoplastic thyroid lesions and assessing tumor behavior.
Main Methods:
- DNA flow cytometry was used to analyze DNA content in 108 thyroid tissue samples.
- Samples included normal tissues, benign tumors (follicular adenomas, multinodular goiters), malignant tumors (papillary and follicular carcinomas), and non-neoplastic lesions (chronic thyroiditis, Graves' disease).
Main Results:
- Aneuploid cell populations were detected in 60% of papillary carcinomas, 67% of follicular carcinomas, 52% of follicular adenomas, and 10% of multinodular goiters.
- No aneuploidy was observed in chronic thyroiditis or Graves' disease.
- While DNA index differed between follicular carcinomas and adenomas, aneuploidy frequency did not significantly differentiate papillary carcinoma subtypes or follicular tumors' malignancy, but was useful in distinguishing neoplastic from non-neoplastic lesions.
Conclusions:
- Flow cytometry analysis of DNA content can help differentiate neoplastic from non-neoplastic thyroid lesions.
- DNA content analysis may not be sufficiently helpful for evaluating the clinical behavior of papillary carcinomas or determining the malignancy of follicular tumors.